Improved Outcome for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Who Stop Ibrutinib +/− Rituximab for Reasons Other Than Progression of Disease

Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_114
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy